4200 MARATHON BLVD., AUSTIN, TX
Announces Reverse Stock Split
Annual Report to Security Holders
Ronald A. Andrews Appointed to Plus Therapeutics Board of Directors
Material disclosure
Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
Departure of Directors; Plus Therapeutics Announces Executive Changes
Investor Presentation
Announces Pricing of Upsized $15 Million Public Offering
Q3
Q2
Q1
Notice of Late Filing for Quarterly Report
Amended Annual Report
FY 2024
RW
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
S-1
Direct Registration System
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
PRER14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
S-1MEF
Correspondence
Submission Upload